Related Experiment Videos

Strategies for the combination therapy of HIV infection

R Yarchoan¹, H Mitsuya, S Broder

¹Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Journal of Acquired Immune Deficiency Syndromes

|January 1, 1990

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

Oncogene·2017

Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population.

Modern rheumatology·2014

PDK1 inhibition is a novel therapeutic target in multiple myeloma.

British journal of cancer·2013

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Cellular and molecular biology (Noisy-le-Grand, France)·2013

The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Cellular and molecular biology (Noisy-le-Grand, France)·2011

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.

Oncogene·2009

See all related articles